title: Hepatitis C: management of side effects in the era of direct-acting antivirals.
abstract: Triple therapy with either boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon-alfa (PEG-IFN) and ribavirin (RBV) has given clinicians a more effective armamentarium and has established a new standard of care for the treatment of chronic hepatitis C (CHC). These advances have come with the caveat of continued adverse effects of dual therapy, with a new set of adverse effects related specifically to the protease inhibitors, BOC and TVR. Hematologic, dermatologic, and gastrointestinal adverse effects require careful monitoring and specific interventions, which will assist in completing therapy and achieving SVR. With appropriate clinical awareness and monitoring, treatment of CHC with triple therapy can be highly successful.
authors.affiliation: University of Chicago Medicine, 5841 South Maryland Ave MC 7120, Chicago, IL 60637, USA. John.Gaetano@uchospitals.edu
authors.forename: John N
authors.initials: JN
authors.lastname: Gaetano
authors.forename: Nancy
authors.initials: N
authors.lastname: Reau
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans
chemical_list: D000998:Antiviral Agents